Biogen Q2 Adjusted EPS $4.02 Beats $3.77 Estimate, Sales $2.46B Beat $2.37B Estimate
Portfolio Pulse from Benzinga Newsdesk
Biogen reported Q2 earnings of $4.02 per share, beating the analyst consensus estimate of $3.77 by 6.63%. However, this is a 23.43% decrease from the same period last year. The company also reported quarterly sales of $2.46 billion, beating the estimate of $2.37 billion by 3.63%, but this is a 5.14% decrease from last year.
July 25, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen's Q2 earnings and sales beat estimates but are down from the same period last year. This mixed result could lead to uncertainty in the market.
While Biogen beat estimates for both earnings per share and sales, the fact that these figures are down from the same period last year could lead to uncertainty among investors. This could potentially impact the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100